| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2004 | WO2003103584A3 Ether substituted imidazopyridines |
| 02/26/2004 | WO2003103575A3 Compounds, compositions, and methods |
| 02/26/2004 | WO2003101374A3 Use of new etonogestrel esters |
| 02/26/2004 | WO2003099337A3 Inclusion complexes of rosiglitazone |
| 02/26/2004 | WO2003099211A3 Mitotic kinesin inhibitors |
| 02/26/2004 | WO2003099203A3 Enteric coated caffeine tablet |
| 02/26/2004 | WO2003098223A3 A method for killing cells by inhibiting histone activity in the cell |
| 02/26/2004 | WO2003097855A3 Small molecule inhibitors of her2 expression |
| 02/26/2004 | WO2003097564A3 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| 02/26/2004 | WO2003096991A3 Amelioration of the development of cataracts and other opthalmic diseases |
| 02/26/2004 | WO2003096990A3 Protein cages for the delivery of medical imaging and therapy |
| 02/26/2004 | WO2003096973A3 A direct cellular energy delivery system |
| 02/26/2004 | WO2003094950A3 A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
| 02/26/2004 | WO2003092791A3 Energetically-controlled delivery of biologically active material from an implanted medical device |
| 02/26/2004 | WO2003090712A3 Compositions for treating hyperemia |
| 02/26/2004 | WO2003090684A3 Polymer compositions containing a macrocyclic triene compound |
| 02/26/2004 | WO2003088970A3 Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| 02/26/2004 | WO2003088906A3 Methods of simultaneously treating ocular rosacea and acne rosacea |
| 02/26/2004 | WO2003086291A3 Urea compositions |
| 02/26/2004 | WO2003083050A3 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 02/26/2004 | WO2003082209A3 Cochleates made with purified soy phosphatidylserine |
| 02/26/2004 | WO2003079978A3 Protease activity of thrombin inhibits angiogenesis |
| 02/26/2004 | WO2003079936A9 Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis |
| 02/26/2004 | WO2003076398A3 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors |
| 02/26/2004 | WO2003075830A3 Oral controlled drug delivery system containing carbamazepine |
| 02/26/2004 | WO2003074008A3 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 02/26/2004 | WO2003070234A9 Alkylating agent combinations in the treatment of cancer |
| 02/26/2004 | WO2003070155A3 Orally administrable pharmaceutical formulation |
| 02/26/2004 | WO2003068156A3 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome |
| 02/26/2004 | WO2003066813A3 MINRs AS MODIFIERS OF INSULIN RECEPTOR SIGNALING AND METHODS OF USE |
| 02/26/2004 | WO2003065992A3 Treating benign prostate hyperplasia with sarms |
| 02/26/2004 | WO2003064443A3 New corticosteroids |
| 02/26/2004 | WO2003062388A3 Inhibition of rna function |
| 02/26/2004 | WO2003061572A9 Anti-inflammatory formulations |
| 02/26/2004 | WO2003060085A3 Mammalian neural stem cells, compositions and uses thereof |
| 02/26/2004 | WO2003059898A3 Eponemycin and epoxomicin analogs and uses thereof |
| 02/26/2004 | WO2003059197A3 The use of sulfonated compounds as a barrier contraceptive |
| 02/26/2004 | WO2003057822A3 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 02/26/2004 | WO2003057144A3 Change inhibitors of dipeptidyl peptidase iv |
| 02/26/2004 | WO2003054019A3 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 02/26/2004 | WO2003053423A3 Inhibition or prevention of infection by bacteria with epa, dha or analogs |
| 02/26/2004 | WO2003051837A3 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) |
| 02/26/2004 | WO2003047517A3 Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa |
| 02/26/2004 | WO2003045334A3 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 02/26/2004 | WO2003043586A9 Compositions for sustained action product delivery |
| 02/26/2004 | WO2003040144A3 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
| 02/26/2004 | WO2003039549A8 Selective antibacterial agents |
| 02/26/2004 | WO2003039476A3 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 02/26/2004 | WO2003039464A3 Antimuscarinic aerosol |
| 02/26/2004 | WO2003039436A3 Pharmaceutical compositions containing oxybutynin |
| 02/26/2004 | WO2003035886A3 Method for preparing heparin from mast cell cultures |
| 02/26/2004 | WO2003034991A3 Taste masking spill-resistant formulation |
| 02/26/2004 | WO2003032990A3 Polymer conjugates of opioid antagonists |
| 02/26/2004 | WO2003032915A3 Viral inhibition by n-docosanol |
| 02/26/2004 | WO2003031987A3 In vitro model for priocidal activity |
| 02/26/2004 | WO2003031381A3 Synthesis of (z)-3,5,4'-trimethoxystilbene, and use thereof |
| 02/26/2004 | WO2003029495A3 Coniosulphides and their derivatives, method for their production and use as medicaments |
| 02/26/2004 | WO2003026614A9 Dosage form containing a confectionery composition |
| 02/26/2004 | WO2003026568A3 Androstanes as androgen receptor modulators |
| 02/26/2004 | WO2003024434A3 Use of a superoxide dismutase mimetic catalyst in the manufacture of a medicament for preventing and treating hiv-mediated central nervous system damage |
| 02/26/2004 | WO2003013541A8 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives |
| 02/26/2004 | WO2003013493A8 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 02/26/2004 | WO2003006425A9 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/26/2004 | WO2002103014A3 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 02/26/2004 | WO2002099047A3 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/26/2004 | WO2002098869A3 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 02/26/2004 | WO2002098501A3 Method and apparatus for treating tumors using low strength electric fields |
| 02/26/2004 | WO2002098424B1 Novel anti-infectives |
| 02/26/2004 | WO2002096351A3 Ultrashort-acting opioids for transdermal application |
| 02/26/2004 | WO2002095005A3 Therapeutic dna vaccination |
| 02/26/2004 | WO2002094322A3 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
| 02/26/2004 | WO2002088120B1 Method for obtaining pioglitazone as an antidiabetic agent |
| 02/26/2004 | WO2002083917A8 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 02/26/2004 | WO2002083683A9 Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists |
| 02/26/2004 | WO2002083067A9 Prodrugs via acylation with cinnamate |
| 02/26/2004 | WO2002080860A3 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
| 02/26/2004 | WO2002066672A3 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
| 02/26/2004 | WO2002057211A8 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 02/26/2004 | WO2002055075A9 Compounds and methods for regulating cell differentiation |
| 02/26/2004 | WO2002055067A3 Fumaric acid derivatives as nf-kappab inhibitors |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002041910A8 Methods and compositions for the treatment of diseases of the eye |
| 02/26/2004 | WO2002036129A3 Topical treatment of mastalgia with arometese inhibitors such as androstendione |
| 02/26/2004 | WO2002030902A8 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 02/26/2004 | WO2002022112A3 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 02/26/2004 | WO2002002812A3 Method for determining the susceptibility to stoke by analysing the ins gene |
| 02/26/2004 | WO2001080715A3 Methods for identifying compounds useful for preventing acute clinical vascular events in a subject |
| 02/26/2004 | US20040039356 Compositions for external preparations |
| 02/26/2004 | US20040039298 Noninvasive measurement of chemical substances |
| 02/26/2004 | US20040039297 Noninvasive measurement of chemical substances |
| 02/26/2004 | US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides |
| 02/26/2004 | US20040039200 1,2,3,4,10,10a-hexahydropyrazino(1,2-a)indole derivatives useful for treating disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, and diabetes |
| 02/26/2004 | US20040039199 4-((3-(7-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo(3.3. 1)non-3-yl)propyl))amino)benzonitrile, benzenesulfonic acid salt, is useful in the prophylaxix |
| 02/26/2004 | US20040039198 Administering to a mammal an aromatic and heteroacromatic substituted imidazole compound to treat diseases: renal disease, wound healing, ucler, ocular disorder, diabetic nephropathy, atherosclerosis, fibrosis, ALzheimer's disease |
| 02/26/2004 | US20040039196 (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039066 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1 |
| 02/26/2004 | US20040039065 Autonomic nerve regulating agent |
| 02/26/2004 | US20040039064 Treating and/or preventing alzheimer's disease and other neurodegenerative diseases; beta-secretase inhibitors |
| 02/26/2004 | US20040039063 Nitroxyl progenitors in the treatment of heart failure |